45,694 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by Invesco Ltd.

Key Points

• Invesco Ltd. has acquired a new position in Amylyx Pharmaceuticals, purchasing 45,694 shares valued at approximately $162,000 during the first quarter.
• Hedge fund activity around Amylyx Pharmaceuticals is significant, with 95.84% of the stock now held by institutional investors after several have recently increased their stakes.
• Amylyx Pharmaceuticals has received positive analyst ratings, including upgrades from Citigroup and Goldman Sachs, with an average rating of "Buy" and a consensus price target of $12.25.

Invesco Ltd. acquired a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 45,694 shares of the company's stock, valued at approximately $162,000. Invesco Ltd. owned 0.05% of Amylyx Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMLX. Valeo Financial Advisors LLC acquired a new stake in shares of Amylyx Pharmaceuticals during the first quarter worth $35,000. Alpine Global Management LLC acquired a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth $45,000. R Squared Ltd raised its holdings in shares of Amylyx Pharmaceuticals by 99.9% during the first quarter. R Squared Ltd now owns 12,736 shares of the company's stock worth $45,000 after acquiring an additional 6,366 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Amylyx Pharmaceuticals by 18.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,188 shares of the company's stock valued at $61,000 after buying an additional 2,653 shares during the last quarter. Finally, Premier Path Wealth Partners LLC acquired a new stake in Amylyx Pharmaceuticals in the 1st quarter valued at $72,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMLX has been the topic of several recent research reports. Jefferies Financial Group initiated coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, June 24th. They issued a "hold" rating on the stock. Wall Street Zen upgraded shares of Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, July 18th. Citigroup initiated coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, June 17th. They issued a "buy" rating and a $12.00 price target on the stock. The Goldman Sachs Group upgraded shares of Amylyx Pharmaceuticals to a "buy" rating and set a $10.00 price target on the stock in a research note on Thursday, July 10th. Finally, UBS Group upgraded shares of Amylyx Pharmaceuticals to a "hold" rating in a research note on Tuesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $12.25.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX opened at $10.44 on Tuesday. The firm has a 50-day moving average of $8.23 and a 200-day moving average of $5.78. Amylyx Pharmaceuticals, Inc. has a one year low of $2.28 and a one year high of $10.55. The company has a market cap of $930.93 million, a PE ratio of -4.18 and a beta of -0.45.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.02). Analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.